GlassScriptPhysician profile
Subhash K Thareja
NPI 1932194420
$2,122.63
in general payments reported to CMS, 2019-2025
26 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $76.19 · 2021: $264 · 2022: $236 · 2023: $298 · 2024: $422 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $362.79 | 2019-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $224.41 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $216.96 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $204.27 | 2022-2025 | |
| Novo Nordisk INC | $143.94 | 2019-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $141.11 | 2019-2021 | |
| Pfizer INC. | $103.53 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.85 | 2019-2025 | Lifevest |
| Biotronik INC. | $73.43 | 2019 | |
| Cvrx, INC. | $66.04 | 2024-2025 | Barostim Neo System |
| Biofrontera INC. | $56.27 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Actelion Pharmaceuticals US, INC. | $54.59 | 2022-2025 | Uptravi |
| Sanofi-Aventis U.S. LLC | $51.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.02 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $42.93 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.84 | 2024 | Mounjaro |
| Smith+Nephew, INC. | $32.76 | 2024 | Renasys Go V2 Home |
| Bayer Healthcare Pharmaceuticals INC. | $31.34 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.41 | 2019 | |
| Kestra Medical Technology Services, INC. | $24.57 | 2024 | Assure Wcd |
| Angiodynamics, INC. | $21.96 | 2022 | |
| Seqirus USA INC | $16.24 | 2024 | Fluad, Flucelvax |
| Boston Scientific Corporation | $14.29 | 2024 | Varithena Administration Pack |
| Esperion Therapeutics, INC. | $14.17 | 2024 | Nexletol |
| Medtronic, INC. | $13.14 | 2023 | Closurefast |
| Medtronic Vascular, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Thareja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.